Vulvovaginal cancer treatment study
Part of Cancer, Women’s health & pregnancy clinical trials.
This study looks at how well treatments like radiation, chemotherapy, or surgery work for people with vulvar or vaginal cancer, and how they affect quality of life. It includes patients treated between 2019 and 2023.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with vulvar or vaginal cancer that has not spread to other parts of the body.
- You received treatment with radiation, chemotherapy, or surgery between January 2019 and December 2023.
- Your medical records are complete enough for the study.
- You do not have metastatic disease at the start of treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is for people with early-stage vulvar cancer that can be surgically removed. It looks at the cancer's HPV and p53 status to decide how much tissue to remove, aiming to reduce side effects while keeping the cancer away.
This trial combines radiation, chemotherapy, and internal radiation therapy to treat vaginal cancer. It aims to see if this approach is safe and effective for patients with different stages of the disease.
This Phase 2 study looks at how vulvar squamous cell cancer (SCC) spreads to the sentinel lymph node, and how findings may guide treatment. It focuses on specific early-stage tumor features and requires that cancer is found in the sentinel lymph node.
This Phase 2 trial compares two treatment approaches for some women with vulvar squamous cell cancer: chemoradiation first, or chemotherapy first followed by surgery. The goal is to see which strategy works better or is safer for tumors that are hard to remove without major pelvic surgery.
This study looks at how vulva cancer returns (recurrence) over time. It aims to improve follow-up care for people who have had this type of cancer.
This trial tests whether combining pembrolizumab with lenvatinib can shrink and control advanced vulvar squamous cell cancer that can’t be fully treated with surgery or strong radiation. It may help some people live longer and better control symptoms, but it also requires close monitoring and specific health criteria.
Hear when a new Vulvo-vaginal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.